Medscape June 21, 2024
CHICAGO — Prominent Chinese oncologist Tony Shu-Kam Mok, MD, who presented as first author of a phase 3 non–small cell lung cancer study at ASCO 2024, made a dramatic swerve in his career path at age 36.
After 20 years in Canada — 7 spent practicing community oncology near Toronto — Dr Mok was visiting family in his native Hong Kong back in 1996 when a job offer there enabled him to revive his early dream of doing academic research. Dr Mok and his family moved back home just before the former British colony was returned to China in 1997.
That leap of faith helped Dr Mok play a role in the global paradigm shift on treating lung cancer. He...
Today's Sponsors
Today's Sponsor